Pharmacovigilance of antiretroviral dolutegravir in the state of Paraná
Acta sci., Health sci
; 44: e53630, Jan. 14, 2022.
Article
in En
| LILACS
| ID: biblio-1367783
Responsible library:
BR513.1
ABSTRACT
The aim of this study was to investigate adverse reactions to Dolutegravir, a drug recently made available by the Unified Health System (SUS) for treating HIV infections. The frequency, severity and sex distribution of adverse reactions to Dolutegravir were identified over the first 18 months of its availability in users in the state of Paraná. Information was obtained through the pharmacovigilance questionnaire prepared by the Ministry of Health, accessed through the Logistics Control System for Medicines(SICLOM). During the study period, dolutegravirwas dispensed to 9,865 patients in the state. However, 9,207 users (93.3%) answered the pharmacovigilance questionnaire. Among them, 1.75% reported 279 adverse reactions. This population was composed mainly of male people (69.57%), in the ratio of 2.29 men for each woman, white (67.08%), aged between 20 and 29 years (26.71%), single (45.34%) and with education between 8 and 11 years of study (41.61%). Gastrointestinal (36.92%) and nervous system (14.34%) disorders were the most prevalent. 77.78% adverse reactions were considered non-serious by users. It can be concluded that dolutegravirhad a low prevalence of adverse reactions in users in the state of Paraná, demonstrating to be safe for use by the population in therapy against HIV, in accordance with clinical trials.
Key words
Full text:
1
Index:
LILACS
Main subject:
HIV Infections
/
HIV Integrase Inhibitors
/
Anti-Retroviral Agents
/
Pharmacovigilance
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Language:
En
Journal:
Acta sci., Health sci
Journal subject:
Medicina
/
Sa£de P£blica
Year:
2022
Type:
Article